Bleeding and stent thrombosis on P2Y12-inhibitors: Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention

D. Aradi, Ajay Kirtane, Laurent Bonello, Paul A. Gurbel, Udaya S. Tantry, Kurt Huber, Matthias K. Freynhofer, Jurrien Ten Berg, Paul Janssen, Dominick J. Angiolillo, Jolanta M. Siller-Matula, Rossella Marcucci, Giuseppe Patti, Fabio Mangiacapra, Marco Valgimigli, Olivier Morel, Tullio Palmerini, Matthew J. Price, Thomas Cuisset, Adnan KastratiGregg W. Stone, Dirk Sibbing

Research output: Article

160 Citations (Scopus)

Abstract

Aims: Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis (ST) and bleeding, standardized and clinically validated thresholds for accurate risk stratification after percutaneous coronary intervention (PCI) are lacking. We sought to determine the prognostic value of low platelet reactivity (LPR), optimal platelet reactivity (OPR), or high platelet reactivity (HPR) by applying uniform cut-off values for standardized devices. Methods and results: Authors of studies published before January 2015, reporting associations between platelet reactivity, ST, and major bleeding were contacted for a collaborative analysis using consensus-defined, uniform cut-offs for standardized platelet function assays. Based on best available evidence for each device (exploratory studies), LPR-OPR-HPR categories were defined as 208 PRU for VerifyNow, 46 U for the Multiplate analyser and 50% for VASP assay. Seventeen studies including 20 839 patients were used for the analysis; 97% were treated with clopidogrel and 3% with prasugrel. Patients with HPR had significantly higher risk for ST [risk ratio (RR) and 95% CI: 2.73 (2.03-3.69), P <0.00001], yet a slight reduction in bleeding [RR: 0.84 (0.71-0.99), P = 0.04] compared with those with OPR. In contrast, patients with LPR had a higher risk for bleeding [RR: 1.74 (1.47-2.06), P <0.00001], without any further benefit in ST [RR: 1.06 (0.68-1.65), P = 0.78] in contrast to OPR. Mortality was significantly higher in patients with HPR compared with other categories (P <0.05). Validation cohorts (n = 14) confirmed all results of exploratory studies (n = 3). Conclusions: Platelet reactivity assessment during thienopyridine-type P2Y12-inhibitors identifies PCI-treated patients at higher risk for mortality and ST (HPR) or at an elevated risk for bleeding (LPR).

Original languageEnglish
Pages (from-to)1762-1771
Number of pages10
JournalEuropean Heart Journal
Volume36
Issue number27
DOIs
Publication statusPublished - júl. 14 2015

Fingerprint

Percutaneous Coronary Intervention
Stents
Thrombosis
Blood Platelets
Hemorrhage
Odds Ratio
clopidogrel
Equipment and Supplies
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Bleeding and stent thrombosis on P2Y12-inhibitors : Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. / Aradi, D.; Kirtane, Ajay; Bonello, Laurent; Gurbel, Paul A.; Tantry, Udaya S.; Huber, Kurt; Freynhofer, Matthias K.; Ten Berg, Jurrien; Janssen, Paul; Angiolillo, Dominick J.; Siller-Matula, Jolanta M.; Marcucci, Rossella; Patti, Giuseppe; Mangiacapra, Fabio; Valgimigli, Marco; Morel, Olivier; Palmerini, Tullio; Price, Matthew J.; Cuisset, Thomas; Kastrati, Adnan; Stone, Gregg W.; Sibbing, Dirk.

In: European Heart Journal, Vol. 36, No. 27, 14.07.2015, p. 1762-1771.

Research output: Article

Aradi, D, Kirtane, A, Bonello, L, Gurbel, PA, Tantry, US, Huber, K, Freynhofer, MK, Ten Berg, J, Janssen, P, Angiolillo, DJ, Siller-Matula, JM, Marcucci, R, Patti, G, Mangiacapra, F, Valgimigli, M, Morel, O, Palmerini, T, Price, MJ, Cuisset, T, Kastrati, A, Stone, GW & Sibbing, D 2015, 'Bleeding and stent thrombosis on P2Y12-inhibitors: Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention', European Heart Journal, vol. 36, no. 27, pp. 1762-1771. https://doi.org/10.1093/eurheartj/ehv104
Aradi, D. ; Kirtane, Ajay ; Bonello, Laurent ; Gurbel, Paul A. ; Tantry, Udaya S. ; Huber, Kurt ; Freynhofer, Matthias K. ; Ten Berg, Jurrien ; Janssen, Paul ; Angiolillo, Dominick J. ; Siller-Matula, Jolanta M. ; Marcucci, Rossella ; Patti, Giuseppe ; Mangiacapra, Fabio ; Valgimigli, Marco ; Morel, Olivier ; Palmerini, Tullio ; Price, Matthew J. ; Cuisset, Thomas ; Kastrati, Adnan ; Stone, Gregg W. ; Sibbing, Dirk. / Bleeding and stent thrombosis on P2Y12-inhibitors : Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. In: European Heart Journal. 2015 ; Vol. 36, No. 27. pp. 1762-1771.
@article{fd88cb4b4fcc4fbf8b92f2e7c929cd3c,
title = "Bleeding and stent thrombosis on P2Y12-inhibitors: Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention",
abstract = "Aims: Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis (ST) and bleeding, standardized and clinically validated thresholds for accurate risk stratification after percutaneous coronary intervention (PCI) are lacking. We sought to determine the prognostic value of low platelet reactivity (LPR), optimal platelet reactivity (OPR), or high platelet reactivity (HPR) by applying uniform cut-off values for standardized devices. Methods and results: Authors of studies published before January 2015, reporting associations between platelet reactivity, ST, and major bleeding were contacted for a collaborative analysis using consensus-defined, uniform cut-offs for standardized platelet function assays. Based on best available evidence for each device (exploratory studies), LPR-OPR-HPR categories were defined as 208 PRU for VerifyNow, 46 U for the Multiplate analyser and 50{\%} for VASP assay. Seventeen studies including 20 839 patients were used for the analysis; 97{\%} were treated with clopidogrel and 3{\%} with prasugrel. Patients with HPR had significantly higher risk for ST [risk ratio (RR) and 95{\%} CI: 2.73 (2.03-3.69), P <0.00001], yet a slight reduction in bleeding [RR: 0.84 (0.71-0.99), P = 0.04] compared with those with OPR. In contrast, patients with LPR had a higher risk for bleeding [RR: 1.74 (1.47-2.06), P <0.00001], without any further benefit in ST [RR: 1.06 (0.68-1.65), P = 0.78] in contrast to OPR. Mortality was significantly higher in patients with HPR compared with other categories (P <0.05). Validation cohorts (n = 14) confirmed all results of exploratory studies (n = 3). Conclusions: Platelet reactivity assessment during thienopyridine-type P2Y12-inhibitors identifies PCI-treated patients at higher risk for mortality and ST (HPR) or at an elevated risk for bleeding (LPR).",
keywords = "P2Y<inf>12</inf>-inhibitors, Platelet reactivity, Stent thrombosis, Bleeding",
author = "D. Aradi and Ajay Kirtane and Laurent Bonello and Gurbel, {Paul A.} and Tantry, {Udaya S.} and Kurt Huber and Freynhofer, {Matthias K.} and {Ten Berg}, Jurrien and Paul Janssen and Angiolillo, {Dominick J.} and Siller-Matula, {Jolanta M.} and Rossella Marcucci and Giuseppe Patti and Fabio Mangiacapra and Marco Valgimigli and Olivier Morel and Tullio Palmerini and Price, {Matthew J.} and Thomas Cuisset and Adnan Kastrati and Stone, {Gregg W.} and Dirk Sibbing",
year = "2015",
month = "7",
day = "14",
doi = "10.1093/eurheartj/ehv104",
language = "English",
volume = "36",
pages = "1762--1771",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "27",

}

TY - JOUR

T1 - Bleeding and stent thrombosis on P2Y12-inhibitors

T2 - Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention

AU - Aradi, D.

AU - Kirtane, Ajay

AU - Bonello, Laurent

AU - Gurbel, Paul A.

AU - Tantry, Udaya S.

AU - Huber, Kurt

AU - Freynhofer, Matthias K.

AU - Ten Berg, Jurrien

AU - Janssen, Paul

AU - Angiolillo, Dominick J.

AU - Siller-Matula, Jolanta M.

AU - Marcucci, Rossella

AU - Patti, Giuseppe

AU - Mangiacapra, Fabio

AU - Valgimigli, Marco

AU - Morel, Olivier

AU - Palmerini, Tullio

AU - Price, Matthew J.

AU - Cuisset, Thomas

AU - Kastrati, Adnan

AU - Stone, Gregg W.

AU - Sibbing, Dirk

PY - 2015/7/14

Y1 - 2015/7/14

N2 - Aims: Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis (ST) and bleeding, standardized and clinically validated thresholds for accurate risk stratification after percutaneous coronary intervention (PCI) are lacking. We sought to determine the prognostic value of low platelet reactivity (LPR), optimal platelet reactivity (OPR), or high platelet reactivity (HPR) by applying uniform cut-off values for standardized devices. Methods and results: Authors of studies published before January 2015, reporting associations between platelet reactivity, ST, and major bleeding were contacted for a collaborative analysis using consensus-defined, uniform cut-offs for standardized platelet function assays. Based on best available evidence for each device (exploratory studies), LPR-OPR-HPR categories were defined as 208 PRU for VerifyNow, 46 U for the Multiplate analyser and 50% for VASP assay. Seventeen studies including 20 839 patients were used for the analysis; 97% were treated with clopidogrel and 3% with prasugrel. Patients with HPR had significantly higher risk for ST [risk ratio (RR) and 95% CI: 2.73 (2.03-3.69), P <0.00001], yet a slight reduction in bleeding [RR: 0.84 (0.71-0.99), P = 0.04] compared with those with OPR. In contrast, patients with LPR had a higher risk for bleeding [RR: 1.74 (1.47-2.06), P <0.00001], without any further benefit in ST [RR: 1.06 (0.68-1.65), P = 0.78] in contrast to OPR. Mortality was significantly higher in patients with HPR compared with other categories (P <0.05). Validation cohorts (n = 14) confirmed all results of exploratory studies (n = 3). Conclusions: Platelet reactivity assessment during thienopyridine-type P2Y12-inhibitors identifies PCI-treated patients at higher risk for mortality and ST (HPR) or at an elevated risk for bleeding (LPR).

AB - Aims: Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis (ST) and bleeding, standardized and clinically validated thresholds for accurate risk stratification after percutaneous coronary intervention (PCI) are lacking. We sought to determine the prognostic value of low platelet reactivity (LPR), optimal platelet reactivity (OPR), or high platelet reactivity (HPR) by applying uniform cut-off values for standardized devices. Methods and results: Authors of studies published before January 2015, reporting associations between platelet reactivity, ST, and major bleeding were contacted for a collaborative analysis using consensus-defined, uniform cut-offs for standardized platelet function assays. Based on best available evidence for each device (exploratory studies), LPR-OPR-HPR categories were defined as 208 PRU for VerifyNow, 46 U for the Multiplate analyser and 50% for VASP assay. Seventeen studies including 20 839 patients were used for the analysis; 97% were treated with clopidogrel and 3% with prasugrel. Patients with HPR had significantly higher risk for ST [risk ratio (RR) and 95% CI: 2.73 (2.03-3.69), P <0.00001], yet a slight reduction in bleeding [RR: 0.84 (0.71-0.99), P = 0.04] compared with those with OPR. In contrast, patients with LPR had a higher risk for bleeding [RR: 1.74 (1.47-2.06), P <0.00001], without any further benefit in ST [RR: 1.06 (0.68-1.65), P = 0.78] in contrast to OPR. Mortality was significantly higher in patients with HPR compared with other categories (P <0.05). Validation cohorts (n = 14) confirmed all results of exploratory studies (n = 3). Conclusions: Platelet reactivity assessment during thienopyridine-type P2Y12-inhibitors identifies PCI-treated patients at higher risk for mortality and ST (HPR) or at an elevated risk for bleeding (LPR).

KW - P2Y<inf>12</inf>-inhibitors

KW - Platelet reactivity

KW - Stent thrombosis, Bleeding

UR - http://www.scopus.com/inward/record.url?scp=84931296689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931296689&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehv104

DO - 10.1093/eurheartj/ehv104

M3 - Article

C2 - 25896078

AN - SCOPUS:84931296689

VL - 36

SP - 1762

EP - 1771

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 27

ER -